CD28/OX40 bispecific antibodies

US12195546B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Gerald Beste · Evergem, BE
• Yanik Bruynooghe · Wondelgem, BE
• Klervi DESRUMEAUX · Paris, FR
• Jennifer KUEHN · Frankfurt am Main, DE
• Charlotte LAHOUTE · Paris, FR
• Rami Lissilaa · La Chaux-de-Fonds, CH
• Alessandro MASIERO · Paris, FR
• Sevim Oezguer Bruederle · Frankfurt am Main, DE
• Benjamin SURATT · Cambridge, US
• Emmanuelle Vigne · L'Haÿ-les-Roses, FR
• Jessica VOSS · Cambridge, US

Key dates

• Filing date: Dec 18, 2023
• Grant date: Jan 14, 2025
• Expiry date: Dec 18, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.